PCAC July 2026 Results: 6 of 7 Peptides Recommended for Compounding, DSIP Rejected

The FDA's Pharmacy Compounding Advisory Committee concluded its two-day hearing on July 24, 2026 — and the outcome was significantly better for the research peptide community than most independent analyses, including our own, predicted.

Six of the seven peptides under review received favorable committee recommendations. Only DSIP (emideltide) was rejected, by the narrowest possible margin of one vote. And the committee did something that almost never happens in FDA advisory panel history: it voted against the FDA's own staff recommendation on every single compound it approved.

Here is exactly what happened, what each vote means, and what comes next — without the hype and without the vendor spin.

The vote outcomes — all seven

The historic detail that matters

The committee voted against the FDA's own written staff recommendation on every single compound it approved. FDA staff had reviewed the evidence on all seven peptides and recommended against adding any of them to the 503A Bulks List — citing insufficient human clinical trial data.

The committee disagreed. Reporters in the room described an audible gasp in the hearing room when the first BPC-157 tally was read². An FDA advisory committee overruling its own agency's scientific staff recommendation is genuinely unusual. Doing it six times in two days, on a set of compounds that have generated significant public attention and regulatory controversy since 2023, is historically notable.

The FDA is not legally required to follow the committee's recommendation. But historically, the agency has generally followed advisory committee recommendations, particularly when the vote margins are clear. Six of the seven votes produced majority recommendations — DSIP being the sole exception.

What each vote actually means

BPC-157, KPV, and TB-500 — the Day 1 sweep

All three received identical vote margins: 8 Yes, 6 No, 1 Abstain — a committee vote to recommend BPC-157¹. The identical margin across three separate compounds suggests the committee reached a consistent position on the broader question of whether repair and healing peptides with substantial preclinical evidence but limited human trial data can appropriately be added to the 503A list.

For BPC-157 specifically — the most discussed and most searched compound in the group — this represents a significant shift in regulatory trajectory. The compound went from Category 2 restricted in 2023, to removed from Category 2 in April 2026, to receiving a favorable compounding recommendation in July 2026. A rulemaking process that could establish a legal prescription pathway is now meaningfully more likely than it was 72 hours ago.

MOTS-c — metabolic peptide gains traction

The metabolic peptide of the group received a slightly wider abstention margin but a clear favorable recommendation. MOTS-c is among the less well-known of the seven compounds publicly, but has genuine research interest in metabolic health and longevity — the same audience interested in GLP-1 class compounds.

Semax and Epitalon — the Day 2 cognitive and longevity compounds

Semax (8-5) and Epitalon (7-4) both received favorable recommendations with relatively comfortable margins. Semax has 40+ years of clinical use in Russia for stroke recovery and cognitive applications. Epitalon has decades of research from Dr. Vladimir Khavinson's program on telomerase activation and circadian biology. Neither has completed Phase III human trials by Western standards — but the committee found the existing evidence sufficient to recommend the compounding pathway.

DSIP — the one rejection

Emideltide, commonly known as DSIP (Delta Sleep-Inducing Peptide), was rejected by the narrowest possible margin: 6 Yes, 7 No. One vote. This was the compound evaluated for opioid withdrawal, chronic insomnia, and narcolepsy — the most clinically ambitious set of indications in the group. The committee's rejection may reflect uncertainty about whether the evidence base for those specific indications was sufficient for the compounding pathway, rather than a broader judgment about DSIP's safety.

A one-vote rejection is not a permanent door closing. DSIP can be renominated for a future PCAC review with additional evidence or a narrower indication scope. The compound remains outside the compounding framework for now.

What this vote does NOT mean

This is the section that matters most for anyone reading headlines today.

A favorable PCAC recommendation does not mean BPC-157, TB-500, or any of the other recommended compounds are now legal to compound in the United States. The PCAC is an advisory committee — its vote is a recommendation to the FDA, not a legal determination.

The path from today's recommendation to a legal compounding pathway involves:

• The FDA reviewing the committee's recommendation and deciding whether to initiate formal rulemaking. This is not automatic.
• If the FDA proceeds: publishing a Notice of Proposed Rulemaking in the Federal Register. Opening a public comment period. Reviewing all comments received. Publishing a Final Rule adding the substances to the 503A Bulks List.
• This process typically takes 12 months or more after the committee recommendation. The earliest realistic timeline for any of these compounds entering the legal compounding pathway is mid-to-late 2027.

Compounding pharmacies should not interpret this vote as permission to begin compounding BPC-157, TB-500, or any other recommended compound. Those doing so would be acting ahead of the legal framework, not within it.

For patients and researchers: the gray market landscape is unchanged today. The regulatory trajectory has improved significantly — the probability that a legal compounding pathway will eventually exist for these six compounds is meaningfully higher today than it was before the hearing. But that pathway does not exist yet.

What we got right — and where we were wrong

We said in our full PCAC tracker and preview coverage that a mixed result was the most realistic outcome — one or two favorable recommendations, the rest deferred or rejected. We were wrong on the scale. Six of seven is not a mixed result. It is a clear committee statement in favor of the compounding pathway for this class of compounds.

We were right that the FDA's own staff recommended against all seven — that prediction was accurate and the outcome confirmed it. The committee's decision to overrule that recommendation is the genuinely surprising element of this hearing.

We were right that DSIP had the most uncertain outcome of the seven — the opioid withdrawal indication was always the most ambitious and the evidence base was the thinnest among the group.

We are publishing this correction and update because accurate information matters more than being right. If the outcome had gone the other way, we would publish that too.

What happens to the gray market now

In the short term: nothing changes. The gray market operates independently of the PCAC process and will continue to do so until the FDA completes formal rulemaking and a legal alternative exists.

In the medium term: if the FDA follows through on rulemaking — which the favorable recommendation makes more likely — licensed 503A compounding pharmacies will eventually be able to prepare BPC-157, TB-500, and the other recommended compounds for patients with valid physician prescriptions. When that happens, pharmaceutical-grade quality controls, endotoxin testing, and accurate dosing verification become available through a legal channel.

The existence of a legal, quality-controlled compounding pathway has historically reduced gray market demand for the same compounds — not eliminated it, but reduced it. Patients with physician access shift to the legal channel. Those without physician access or who prefer self-directed research continue to use the gray market.

The enforcement pressure on gray market vendors is independent of the PCAC process and is unlikely to ease regardless of today's outcome. The vendor consolidation of 2025-2026 was driven by FDA enforcement posture and pharmaceutical company litigation — neither of which is affected by the committee's recommendation.

Next steps to watch

• FDA response to the committee recommendation: the FDA will publish its response — either initiating rulemaking or declining to do so. Watch the Federal Register.
• The February 2027 PCAC hearing: five additional peptides are scheduled for review at a second hearing before February 2027. ThePeptide.expert will cover this hearing the same way we covered the July hearing — with a tracker, a public comment guide, and real-time outcome reporting.
• DSIP renomination: given the one-vote margin, watch for a future DSIP renomination with either additional evidence or a narrower indication scope.

ThePeptide.expert will update the regulatory tracker page and individual peptide profiles with any significant developments as they occur.